MedTrace Logo

Nebulized Hypertonic Saline for Inpatient Use in COPD

NCT02266875 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2017-11-22

Study results available
· View outcomes & findings →

Summary

A comparison of albuterol treatments using hypertonic saline (3%) versus standard saline (0.9%) in patients with admitted patients COPD in regard to Modified Borg Dyspnea scale scores after 4 treatments within 24 hours.

Conditions

Interventions

DRUG

hypertonic saline

DRUG

standard saline

Sponsors & Collaborators

  • OhioHealth

    lead OTHER

Principal Investigators

  • Kruti Patel, DO · OhioHealth

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2017-01-30
Completion
2017-01-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02266875 on ClinicalTrials.gov